Study details
Enrolling now
CLEAR HIV Trial
Priscilla Hsue, MD
NCT IDNCT05488431ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
121
Study length
about 5 years
Ages
40+
Locations
3 sites in CA, TX
What this study is about
Researchers are testing whether Bempedoic acid, a medication, can lower cholesterol and inflammation in people with HIV who have heart disease or risk factors for it. The trial will last 1827 days and involve approximately 121 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Bempedoic acid
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
bempedoic acid
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Hb A1c Endpoint, IL-6 Endpoint, Triglycerides Endpoint
Body systems
Cardiology / Heart, Immune, Infectious